Idifarma invests in automatic capsule filling capabilities
Investment enables the CDMO to provide a one-stop-shop service from lab-scale development to manufacturing of clinical batches and dossier compilation to specialised commercial manufacturing.
Idifarma, a Spanish contract development and manufacturing organisation (CDMO) has expanded its GMP manufacturing offering with an investment in automatic capsule filling equipment.
Idifarma has acquired a Bosch GKF-702 capsule filling machine, capable of manufacturing 3,000-42,000 capsules per hour. The new equipment will be installed at the CDMO’s EU-GMP approved plant in Pamplona, Spain, in early 2017.
Commenting on the investment, Luis Oquiñena, general manager and co-founder of Idifarma says: “This is a significant milestone in our journey so far, helping us to become a leading CDMO for small-scale niche products in solid oral forms.
“Idifarma will continue to keep its contract manufacturing focus on specialised, low-volume pharmaceutical products where we can add real value to our clients’ projects involving innovative drugs and niche generics.
“This investment will also include the enlargement of our GMP plant with new rooms and capacity to handle high potency drugs, another clear differentiation and focus area for Idifarma.”
In addition to improving Idifarma’s contract manufacturing capabilities, the GKF-702 will also feature a 'lab kit', enabling the use of the machine during pharmaceutical development, resulting in a more efficient use of APIs and less wastage.
The new machine will benefit from other equipment that is already installed at Idifarma’s GMP plant including a Hüttlin Oyster high-shear mixer and dryer for wet granulation processes, bin blenders with capacity up to 70 kg and a Clinipack IMA blistering machine, with the ability to work with Alu/Alu or any thermo-formable material. Idifarma can also handle narcotics and low-humidity requirements.
Luis Oquiñena continued: “We are confident that this new investment will not only attract clients interested in production, but also contract development projects in hard capsule form in the coming months.
“Our customers can now benefit from a one-stop-shop service from lab-scale development to manufacturing of clinical batches and dossier compilation to specialised commercial manufacturing,” added Luis.
The investment in capsule filling equipment coincides with the 15th anniversary of Idifarma, which will grow its revenue in 2016 by over 25%. The team recently reached 100 people, with 50% of business now coming from outside of Spain.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance